INTRODUCTION

World Health Organization recognized coronavirus disease 2019 (COVID-19) as a pandemic on March 11, 2020 [1]. As of April 24, 2020, 2,732,702 cases of COVID-19 have been reported worldwide, resulting in 191,150 deaths [2].

The first case of COVID-19 in Ukraine was diagnosed on March 3, 2020 in Chernivtsi and the first lethal case was reported on March 13, 2020. As of April 24, 2020 7,647 cases of COVID-19 have been reported in Ukraine, among these cases 193 caused death (2.52% lethality), 601 patients (7.86% of cases) have recovered [2].

The feature of COVID-19 pandemics in Ukraine is that virus cause disease in women (56.0%) more often than in men (44.0%). But there are more male patients in other countries [2]. Although there are more male deaths (51.3%) than female (48.7%) in Ukraine. Deaths have occurred in 18-29 years old patients (1%), 30-49 years old patients (14%), in 50-69 years old patients (48%), in 70 y.o. and older patients (38%) [3]. 85% of all deaths were over 50 years of age. 79% of patients who died from COVID-19 had severe cardiovascular diseases, diabetes mellitus (DM), neoplasms, renal diseases, respiratory disorders and obesity. In total, co-morbidities (one or several) have been cardiovascular diseases (74%), diabetes mellitus (22%), lungs diseases (9%), neoplasms (8%), renal diseases (7%) [3].

It has been published in Ukraine and all over the world that certain groups of patients have a risk of COVID-19 due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. These are patients with arterial hypertension, cardiovascular diseases and diabetes mellitus. The main mentioned risk factors of COVID-19 are advanced age, arterial hypertension, diabetes mellitus, COPD, CVD and cerebrovascular disease [4].

Moreover, diabetes is called both a risk factor for COVID 19, and a risk factor for respiratory failure, and a risk factor for a fatal outcome. For patients with diabetes, it’s almost like a verdict. Is it true that patients with diabetes are doomed to poor results? The effort to answer this question was the purpose of this study.

THE AIM

The aim was to investigate the causes of the negative impact of diabetes mellitus co-morbidity on the onset and development of COVID-19 in diabetic patients.

MATERIALS AND METHODS

Electronic databases of MEDLINE and Google Scholar were searched using keyword searches. The search was limited to English-language literature. Keywords were COVID-19, diabetes mellitus, hyperglycemia, diabetic ketoacidosis. 136 publications were initially identified. Articles were published between December 2019 and April 24, 2020.

REVIEW AND DISCUSSION

In 12 Chinese studies included 2108 patients with confirmed COVID-19 and mean age 49.6 years the prevalence of diabetes was 10.3% [5]. For comparison, total prevalence of diabetes in China in 2013 was 10.9% and the prevalence among people aged 40-59 years was 12.3% [6]. A similar situation is in Europe. In Padua, located at the center of an outbreak, among 146 hospitalized patients with confirmed
Table I. The prevalence of diabetes in COVID-19 patients

<table>
<thead>
<tr>
<th>Authors</th>
<th>Country</th>
<th>Number of patients</th>
<th>Sex (male/female)</th>
<th>Age (median)</th>
<th>Diabetic patients (%) in region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fadini GP, et al. [10]</td>
<td>Italy, Padua</td>
<td>146</td>
<td>-</td>
<td>Mean: 65.3</td>
<td>11,0%</td>
</tr>
<tr>
<td>Fadini G.P., et al. [10]</td>
<td></td>
<td>2108</td>
<td>-</td>
<td>Mean: 49.6</td>
<td>12,3%</td>
</tr>
<tr>
<td>CDC COVID-19 Response</td>
<td>USA</td>
<td>7162</td>
<td>-</td>
<td>10,9%</td>
<td>≥9%</td>
</tr>
<tr>
<td>Longato E, et al. [20]</td>
<td></td>
<td></td>
<td></td>
<td>10,9%</td>
<td></td>
</tr>
<tr>
<td>Wang L, et al. [21]</td>
<td></td>
<td></td>
<td></td>
<td>10,9%</td>
<td></td>
</tr>
</tbody>
</table>

* – the prevalence of diabetes was investigated in certain region according to:
1 – WHO and “IDF Diabetes Atlas 2019” [19];
2 – Longato E, et al. (2020) [20];

Table II. The prevalence of COVID-19 in diabetic patients due to condition severity and treatment results

<table>
<thead>
<tr>
<th>Authors</th>
<th>Country</th>
<th>Number of patients</th>
<th>Age (median)</th>
<th>Mild symptoms</th>
<th>Severe symptoms</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fadini GP, et al. [10]</td>
<td>Italy</td>
<td>355</td>
<td>80.5 (31-103)</td>
<td>-</td>
<td>-</td>
<td>43.5%</td>
</tr>
<tr>
<td>CDC COVID-19 Response</td>
<td>USA</td>
<td>7162</td>
<td>6%</td>
<td>24%</td>
<td>32%</td>
<td></td>
</tr>
<tr>
<td>Bhattacharj PK, et al. [25]</td>
<td>USA</td>
<td>24</td>
<td>64±18</td>
<td>58%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu J, et al. [26]</td>
<td>China</td>
<td>280</td>
<td>43,12±19,02</td>
<td>3.05%</td>
<td>33,73%</td>
<td></td>
</tr>
<tr>
<td>Leung C. [27]</td>
<td>China</td>
<td>46</td>
<td>70.6</td>
<td>-</td>
<td>-</td>
<td>26.2%</td>
</tr>
<tr>
<td>He XW, et al. [28]</td>
<td>China</td>
<td>54</td>
<td>Mediana: 68</td>
<td>24.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu C, et al. [31]</td>
<td>China</td>
<td>201</td>
<td>Mediana: 51</td>
<td>14%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Health Center [3]</td>
<td>Ukraine</td>
<td>98</td>
<td>-</td>
<td>22%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deng SQ, et al. [32]</td>
<td>China</td>
<td>45</td>
<td>-</td>
<td>22%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang JJ, et al. [33]</td>
<td>China</td>
<td>140</td>
<td>Mediana: 57</td>
<td>11,0%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SARS-CoV-2 infection and a mean age of 65.3 years, 13 had pre-existing diabetes (a prevalence was 8.9%) [5]. For comparison, the prevalence of diabetes in the same region in 2018 was 6.2% overall and 11.0% among people aged 55–75 years (mean 65) [7].

According to the meta-analysis, which included 76,993 patients, the pooled prevalence of diabetes in people infected with SARS-CoV-2 was 7.87% [8]. The data from other study, that show the prevalence of diabetes in COVID-19 patients, is in Table I.

According to this analysis we can conclude that the prevalence of diabetes in COVID-19 patients corresponds to the prevalence of DM in certain regions and in the world. So the first main conclusion of this study is that diabetes mellitus co-morbidity does not increase the probability of development COVID-19 and diabetes is not the risk factor of COVID-19.

Thus, diabetes is not a verdict, diabetic patients can have COVID-19 with the same frequency as other people. But, are there any other dangers for this patients? We reviewed data on the to discover the influence of patient’s condition,
place of treatment and diabetes co-morbidity on the results of treatment.

Wu J, et al.(2020) described in their study, which included 280 cases of COVID-19, that significantly more patients from severe group had diabetes in comparison to mild group (33.73% vs 3.05%, P = 0.042) [22].

58% of patients in ICU had diabetes; all these patients had respiratory insufficiency and 75% of patients needed mechanical ventilation [16]. Wang A, et al. (2020) in their study published other data but the trend is the same: more ICU patients with COVID-19 had diabetes than in other departments (22.2% vs 5.9%) [23].

According to Fadini GP, et al. (2020) the prevalence of diabetes among 355 patients who died was 35.5%. In 2018 the prevalence of diabetes in Italy among people with the same age range and sex distribution was 20.3%. Thus, the rate ratio of diabetes among patients who died from SARS-CoV-2 infection compared to the general population was 1.75. The authors concluded that diabetes may not increase the risk of SARS-CoV-2 infection (we have agreed with this yet) but can worsen the outcome of this new coronavirus disease [10].

The other results of this analysis are described in Table II.

The analysis of these data allows us to conclude that patients with severe course of COVID-19 had diabetes more often. Wu C., et al.(2020) had next data: patients with mild course of disease had diabetes in 5.1% of cases, in 19% of ICU patients and in 25% of patients who died [31]. Similar data was published in American study by CDC COVID-19 Response Team. The prevalence of diabetes in this study was 6% in mild group, 24% in non-ICU severe patients and 32% in ICU patients [24]. 22% of patients who died in Ukraine had diabetes [3], while total prevalence of diabetes in Ukraine according to WHO is 5-6% [19].

Thus, we can make second conclusion that previous diabetes can contribute the complications of COVID-19, patient's severe condition and can increase the mortality.

We should consider why the course of infection in diabetic patients is more severe and why are the results worse (while the incidence of COVID-19 is the same in diabetic patients and people without diabetes)?

Firstly, disorders of autonomic innervation of heart (cardiac hypoesthesia syndrome) leads to afferent autonomic nerve fibers injury. These fibers conduct nerve impulses which are connected with pain due to myocardial injury. That is why silent myocardial infarction is common in diabetic patients [34, 35]. The same situation can take place in diabetic patients with COVID-19: patients do not pay much attention to their symptoms, which leads to inadequate treatment. As a result, treatment is delayed, complications develop, the outcome is worse.

Secondly, there is information that SARS-CoV-2 can lead to temporary dysfunction of pancreatic islets [36]. There is information that coronaviruses can entry in the human cells with help of dipeptidyl peptidase 4 (DPP-4). This protein takes part in insulin modulation, glucose metabolism and glucagon degradation (as GLP-1) [37,38]. Hyperglycemia in COVID-19 patients can be caused by this or similar mechanisms [39].

The third possible reason of disease course severity is an influence of some medications often used by diabetic patients, for example, angiotensin converting enzyme (ACE) inhibitors. However, given the insufficient evidence base, the European Medicine Agency (EMA) advises do not interrupt the use of ACE inhibitors during COVID-19 pandemics [40].

Finally, diabetes is a risk factor for the progression and prognosis of COVID-19. Guo W, et al.(2020) found that COVID-19 patients without other comorbidities but with diabetes were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism [41]. Furthermore, serum levels of inflammation-related bio-markers such as IL-6, C-reactive protein, serum ferritin and coagulation index, D-dimer, were significantly higher (P < 0.01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory reactions leading to rapid deterioration of COVID-19 [41].

All mentioned mechanisms can explain the fact that course of COVID-19 in diabetic patients is more severe and has multiple complications and worse results of treatment.

**Specific measures of prophylaxis of COVID-19 in patients with diabetes:**

1. People with diabetes should strictly follow these measures and avoid contacts with relatives and friends because of high possibility of COVID-19.
2. It is important that people with diabetes maintain a good glycemic control, as it might help in reducing the risk of infection and also the severity. More frequent monitoring of blood glucose levels (with use of self-monitoring blood glucose) is required Good glycemic control may decrease chances of superadded bacterial pneumonia.
3. Patients with diabetes should continue to use anti-hypertensive drugs, for example ACE inhibitors (the recommendation can change according to WHO).
4. Attention to nutrition and adequate protein intake is important. Any deficiencies of minerals and vitamins need to be corrected. Delivery of food and drugs should be organized during quarantine.
5. Patients with diabetes should do exercise regularly at home during quarantine.
6. Patients should be in contact with endocrinologist and general practitioner. Face-to-face meeting in hospitals are not recommended to diabetic patients because of crowding.
7. We recommend to use phone calls, video-calls, e-mails to maintain the contact with medical team for disease controlling.
8. Patients with diabetes are recommended to plan their actions in case of COVID-19. It is important to have enough means for frequent monitoring of blood glucose at home.
CONCLUSIONS
1. Diabetes mellitus is not a verdict. Diabetic patients can have COVID-19 with the same frequency as other people. And diabetes mellitus co-morbidity does not increase the probability of development COVID-19.

2. Previous diabetes can contribute the complications of COVID-19, patient’s severe condition and can increase the mortality.

3. The reasons for the negative results of COVID 19 treatment in patients with diabetes may be: features of autonomic innervation in patients with diabetes, impaired function of pancreatic islet cells due to the influence of SARS-CoV-2, use of some cardiac drugs, expression of inflammatory factors due to infection.

Based on our own experience and analysis of international publications [34, 42, 43], we consider it necessary to formulate recommendations for diabetes patients in the context of the COVID 19.

REFERENCES


ORCID and contributionship:
Oleksandr A. Halushko: 0000-0001-7027-8110 A, B, F
Maryna A. Trishchynska: 0000-0002-1022-0635 B, D
Tetiana M. Povietkina: 0000-0002-9442-2188 D, E
Mariana V. Boliuk: 0000-0002-9394-4179 E, F

Conflict of interest:
The Authors declare no conflict of interest.

CORRESPONDING AUTHOR
Oleksandr A. Halushko
Shupyk National Medical Academy of Postgraduate Education, 9 Doroohozhynska st., 04112 Kyiv, Ukraine
tel:+38 095 481 55 77
e-mail: o.halushko@ukr.net

Received: 22.08.2020
Accepted: 30.10.2020

A – Work concept and design, B – Data collection and analysis, C – Responsibility for statistical analysis, D – Writing the article, E – Critical review, F – Final approval of the article